Achieving bladder control. Treatment in the primary care setting.
Maloney
Cynthia M
CM
Seton Health Incontinence Treatment Center, Troy, N.Y., USA.
Cafiero
Madeline
M
D001559:Benzhydryl Compounds / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D003408:Cresols / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008333:Mandelic Acids / Q000627:therapeutic use; D008487:Medical History Taking / Q000379:methods; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D009722:Nurse Practitioners; D009730:Nursing Assessment / Q000379:methods; D010665:Phenylpropanolamine; D010808:Physical Examination / Q000379:methods; D011320:Primary Health Care / Q000379:methods*; D012017:Referral and Consultation; D014039:Toilet Training; D000068737:Tolterodine Tartrate; D014481:United States / Q000453:epidemiology; D014549:Urinary Incontinence / Q000145:classification / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*
D001559:Benzhydryl Compounds; D018680:Cholinergic Antagonists; D003408:Cresols; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C005419:oxybutynin